Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency;…
An institutional-grade, numbers-driven thesis on ETON — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of August 16, 2026, TradersQuant's model rates Eton Pharmaceuticals, Inc. (ETON) 57/100 with a 12-month base-case forecast of $66.67 — +13.3% versus the current price of $58.86. Eton Pharmaceuticals, Inc. trades at $58.86 in the Healthcare sector, with a market capitalisation of $1.61B. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month analyst consensus price target for ETON is $66.67, implying +13.3% versus the current price. The model's 12-month scenario range runs from $108.37 (bear) to $126.70 (bull), with a base case of $115.41.
On the fundamentals, Eton Pharmaceuticals shows a P/E of 126.6, trailing revenue of $80.0M, revenue growth of +104.9% YoY. This page also tracks ETON's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
ETON currently carries a TradersQuant composite score of 57/100, which we read as a neutral-to-watch signal. The Wall-Street analyst consensus is "Buy". Our 12-month price target of $66.67 implies +13.3% from $58.86. This is research, not financial advice — always combine it with your own judgement.
The analyst consensus price target for ETON is $66.67, about +13.3% versus the latest price of $58.86. Consensus is based on 7 analysts.
TradersQuant's 12-month model forecast for ETON is a base case of $115.41, ranging from $108.37 (bear) to $126.70 (bull), an expected return of +96.1%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for ETON over the next 12 months is $115.41 in the base case (bear $108.37, bull $126.70), versus today's price of $58.86. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for ETON — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates ETON's fair value at $66.67, implying +13.3% of expected upside versus the current price.
Eton Pharmaceuticals does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
